iBio shares surge 20.62% after-hours as management unveils AI-driven long-acting antibody programs targeting obesity and cardiometabolic diseases.

iBio, Inc. (IBIO) surged 20.62% in after-hours trading following management's announcement of a long-acting antibody pipeline targeting obesity and cardiometabolic diseases. The news highlighted AI-driven discovery methods and a dual Australia-U.S. regulatory strategy, emphasizing key milestones such as IND filings, first-in-human trials, and strategic partnerships. The disclosure, made during the Evercore ISI HealthCONx Conference on Dec. 4, 2025, underscored the company's focus on leveraging its AI platform to address unmet medical needs in obesity, supported by a robust cash position. This development aligns with recent preclinical advancements in immuno-oncology and antibody research collaborations, reinforcing investor confidence in the firm's transformative pipeline.